Reading the Filings the Promoters Hope You'll Skip

The setup is always the same.

A cannabis ticker shows up on Stocktwits with a green rocket emoji. The price is $0.0003. A press release that morning announces a "transformative partnership" with a dispensary in a state where cannabis is "projected to exceed $5 billion by 2028." The company website features mushroom gummies and pain creams. Volume is up 800%. The chat is loud.

You have ninety seconds to decide whether to buy.

If you've spent any time in OTC cannabis, you've seen this play. The sector attracts more promotional activity than almost any other small-cap category — and there's a structural reason for it. Federal Schedule I status pushed legitimate cannabis operators off major exchanges, leaving the OTC market with a heavy concentration of cannabis-adjacent shells, half-real wellness brands, and outright pumps. Real cannabis enthusiasm provides cover for fake cannabis companies. The legitimate ones get harder to find every quarter.

This isn't a piece telling you not to trade these names. Plenty of Green Brief readers enjoy the speculation, and that's your call to make. This is a piece teaching you to read the filings the promoters don't want you to read — so you can tell the difference between a real, struggling, undervalued cannabis micro-cap and a vehicle for one person to issue shares to retail at will.

There are five questions to ask. Most of the worst names fail three or more.

1. What was this company before it was a cannabis company?

Pull the SEC EDGAR record for the CIK. Not the trading symbol — the underlying CIK number, which persists across name changes.

If the same legal entity has been a film financing company, a cybersecurity startup, an auction marketplace, and now a CBD/mushroom wellness brand — all within ten years — you're looking at a serial shell. The corporate name follows whatever retail narrative is hot. Each pivot generates fresh promotional press releases. None of the prior businesses produced material revenue.

This pattern is everywhere in OTC cannabis. The shell gets repurposed, retail buys the new story, dilution funds operations until the next pivot. The underlying entity is a regulatory chassis with a CEO, a transfer agent, and a wire service contract. The "business" is the share issuance.

Search EDGAR for the CIK and read the historical filings in chronological order. Ten minutes will tell you whether you're looking at a real operating company or a shell on its fourth costume.

2. How many authorized shares are there, and who controls the voting?

Open the most recent 1-A, 1-A POS, or annual report. Find two numbers.

Authorized common shares. This is the ceiling on how many shares can ever be issued. If it's in the billions — five billion, ten billion, twenty-five billion — the company has structural permission to dilute you into oblivion before any shareholder vote could stop it.

Series A or Series B Preferred voting rights. This is the one most retail investors miss, and it's the single most important disclosure in any OTC filing.

Look for language like "the shares of Series A Preferred Stock shall vote together with the shares of common stock as a single class and shall represent [X]% of all votes entitled to be voted at any annual or special meeting." If X is 51% or higher — and in OTC cannabis it's often 80% — whoever holds that Preferred class controls every vote regardless of what common shareholders do. Reverse splits, dilution, name changes, asset sales: all approved by one person.

When you see this structure, the issuer's filings will sometimes be unusually candid about it. You'll find sentences explaining that the Preferred voting class "precludes current and future owners of our common stock from influencing any corporate decision." That language exists because the SEC requires it. Read it.

If you take one thing from this piece, take this one. Authorized share counts and dilution are visible problems people already worry about. The Series A Preferred with super-majority voting control is the trap nobody talks about, and it's the single fastest way to identify which side of the ticker you're on.

3. Does the press release math match the financial filings?

This is the cleanest test in the toolkit.

Pull the most recent audited revenue figure from the 1-K or 10-K. Not the press release. The audited filing. Then look at the promotional language from the same period.

If a company press-released "1,400% revenue growth" and "projected revenues exceeding $10 million" while the audited statements show $178,000 in trailing-twelve-month revenue, the gap isn't a small-cap reporting lag. It's a deliberate reframing. The 1,400% is technically calculated from a near-zero base over an arbitrary window. The $10M projection has no basis in capacity, distribution, or order book. The numbers don't connect to anything that produced them.

The legitimate version of this exists too. Real small cannabis companies often grow fast off small bases, and their PR will reflect that. The difference is checkable. If the audited revenue trajectory is matching the PR claims even directionally, the company is at least reporting honestly. If the gap between PR and audited reality is 50x or 100x, you're not reading press releases — you're reading marketing materials targeted at retail investors who won't pull the filing.

4. Where do the press releases come from, and how often?

Look at the wire service distributing the announcements. Access Newswire, IBN (InvestorBrandNetwork), GlobeNewswire — these are paid distribution services. Companies pay for placement. The distribution itself doesn't validate the news.

Then look at cadence. A real operating cannabis company puts out maybe four to eight press releases a year — earnings, major contracts, regulatory updates, leadership changes. A pump puts out one or two per week. Every minor event becomes a press release. Every dispensary partnership "positions the company for unprecedented growth." Every product launch "taps into a $60 billion market."

The pattern matters because press releases are the fuel for the share issuance. Each release moves the price up briefly, creating a window to sell shares from the company's authorized pool into retail demand. The actual deal sizes — when disclosed — are tiny relative to the language. A "transformative partnership" turns out to be a $5,000 trial order. A "manufacturing agreement" is an LOI with no minimum commitments.

When the cadence is weekly and the language is always cosmic, the press releases aren't news. They're inventory turnover.

5. What do the actual filings say about cash and dilution history?

This is the closer.

Pull the balance sheet. Look at total cash. If a company claiming to be expanding into Latin America, signing dispensary deals, and launching new product lines reports $82 in cash on its most recent balance sheet — that is a real number from a real OTC cannabis filing, not a hypothetical — the operations being described aren't being funded by operations. They're being funded by share issuance.

Then look at the share count history. If outstanding shares went from 200 million to 1.8 billion, to a 1-for-300 reverse split back down to 6 million, to a fresh dilution back up to 4 billion — you're watching the cycle. The reverse split isn't a turnaround. It's the reset that makes the next dilution cycle possible by getting the price back up to where retail will buy again.

This is the mechanic. Authorize billions of shares. Issue them slowly via PR-driven price spikes. When the price hits the floor, reverse-split to reset. Repeat.

What a real OTC cannabis play looks like

This shouldn't be all warning. Some legitimate cannabis companies do trade OTC, often because they can't list on NASDAQ or NYSE due to federal scheduling. They tend to share certain features:

• Files full 10-K and 10-Q reports with the SEC, not just 1-A offering circulars
• Audited financials from a recognizable PCAOB-registered audit firm
• Capped authorized share count in the hundreds of millions, not billions
• No super-voting Preferred class, or one held by a credible operator with skin in the game
• Revenue trajectory in the filings actually matches the press releases — not 100x off
• Press releases tied to real material events — quarterly results, regulatory milestones — not weekly promotional drops
• Cash position consistent with operations — not double-digit dollars in the bank while announcing global expansion

These exist. They're harder to find than the pumps because the pumps spend money on promotion and the legitimate names don't. That's the irony of the OTC cannabis market: the loudest tickers are usually the worst, and the quiet ones are where the real opportunities sit.

The bottom line

Speculative trading on OTC cannabis is a legitimate thing for sophisticated investors who understand they're playing against the share-issuing entity itself. The math is brutal at sub-penny prices — slippage alone can eat a 20% move — but if you want to play it, play it knowing what you're holding.

What you can't afford to do is mistake a pump for a real company. The five-question test above takes about fifteen minutes per ticker. It will save you from the worst of the sector while leaving plenty of room to find the real names that just happen to trade in the wrong tier.

Cannabis is a real market. The sector is genuinely growing. The opportunity for legitimate small-cap investing in cannabis is real. But every legitimate name shares the same exchange floor with vehicles whose entire purpose is to extract money from retail. Knowing which is which is the first skill, before any of the rest matter.

Read the filings. The promoters are counting on you not to.